hematopoietic pharm

Filgrastim

Neutropenia drug; G-CSF that increases neutrophil production. Major adverse effect: bone pain. Give at least 24 hr after chemotherapy.

Vinblastine

Vinca alkaloid that inhibits mitosis; strongly associated with Hodgkin lymphoma. Think: BLAST Hodgkin with vinBLASTine.

Vincristine

Vinca alkaloid that inhibits mitosis; used in leukemia/lymphoma. Major dose-limiting toxicity: neurotoxicity.

Vinca alkaloids

Mitotic inhibitors that prevent cancer cells from completing cell division.

Antitumor antibiotics

Bind/interfere with DNA. Major toxicity: cardiac toxicity.

Dexrazoxane

Helps reduce cardiac damage from antitumor antibiotics.

corticosteriods

Suppress lymphocyte division; used in leukemia and lymphoma. Long-term use can cause Cushing syndrome manifestations.

Antimetabolites

Disrupt materials cancer cells need for DNA/RNA production and cell growth.

Purine/Pyrimidine analogs

Interfere with DNA and RNA synthesis/function.

Alkylating agents

Bind/change DNA and prevent cell division; powerful immunosuppressants.

Targeted therapy

Blocks a specific cancer target involved in growthprogresssion or survival

Monoclonal antibodies (MABs)

Bind specific target cells; cancer cells may die or be marked for immune destruction.

Ferrous sulfate

Iron replacement used for iron-deficiency anemia. Can cause dark stools and constipation; avoid antacids.

Vitamin C (ascorbic acid)

Helps increase iron absorption.

Deferoxamine

Antidote used for iron toxicity/overdose.

Cyanocobalamin

Vitamin B12 replacement used for pernicious anemia/B12 deficiency.

Rituximab + corticosteroids

Used in autoimmune hemolytic anemia to decrease immune destruction of RBCs.

Hydroxyurea

Antimetabolite used in sickle cell disease; reduces RBC deformity/sickling. Major risk: myelosuppression.

L-glutamine

Reduces oxidative stress and helps RBC flexibility in sickle cell disease; can reduce vaso-occlusive crises.

Crizanlizumab (Adakveo)

Monoclonal antibody that blocks P-selectin

Casgevy / Lyfgenia

Gene therapies for sickle cell disease using the patient's own modified stem cells.

Deferasirox

Iron chelator for transfusion-related iron overload in thalassemia. Watch liver/kidney injury and GI bleeding.

Deferiprone

Iron chelator for iron overload in thalassemia. Major risk: agranulocytosis/neutropenia.

Mitapivat (Pyrukynd)

Increases pyruvate kinase activity, improving RBC energy/lifespan and reducing
hemolysis

Luspatercept-aamt

Erythroid maturation agent used in beta-thalassemia; helps increase RBCs. Watch for clots and bone pain.

Luspatercept-aamt

Erythroid maturation agent used in beta-thalassemia; helps increase RBCs. Watch for clots and bone pain

Betibeglogene (Zynteglo

Gene therapy for beta-thalassemia using the patient's modified stem cells to produce functional hemoglobin

Therapeutic phlebotomy

First-line treatment for polycythemia vera; removes blood to reduce RBC mass and blood viscosity

low dose aspirin

used in polycthemia vera to help reduce clotting risk

Ropeginterferon alfa-2b-njft
(BESREMi)

Cytoreductive therapy for polycythemia vera; reduces bone-marrow overproduction of
cells.

Ruxolitinib (Jakafi)

Targeted therapy for polycythemia vera that blocks JAK signaling to control RBC
production. Monitor CBC and infection risk